We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00306631
Recruitment Status : Completed
First Posted : March 24, 2006
Last Update Posted : June 3, 2009
Information provided by:

March 22, 2006
March 24, 2006
June 3, 2009
January 2006
April 2008   (Final data collection date for primary outcome measure)
Antitumor activity, based on the objective response rate [ Time Frame: every 8 weeks ]
Not Provided
Complete list of historical versions of study NCT00306631 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Advanced or Metastatic Breast Cancer
This phase 2 study will determine the antitumor activity, based on the objective rate, of oral MKC-1, administered twice daily for 14 consecutive days every 4 weeks, in patients with advanced or metastatic breast carcinoma. The study will also evaluate the safety and response duration in patients, time to tumor progression, and overall survival in patients following MKC-1 therapy.
Not Provided
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Breast Cancer
Drug: MKC-1
Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle
Experimental: 1
Intervention: Drug: MKC-1
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
November 2008
April 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the breast
  • 18 years or older
  • Karnofsky performance status greater than or equal to 70%
  • Radiographic or physical examination evidence of at least one site of unidimensionally-measurable disease, using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria
  • Must have failed both a taxane and an anthracycline, given sequentially or in combination, either in an adjuvant or metastatic setting
  • All acute toxicity of any prior chemotherapy, surgery or radiotherapy must have resolved to National Cancer Institute Common Toxicity Criteria (NCI CTC) Grade less than or equal to 1
  • Lab results, within 10 days of MKC-1 administration:

    • Hemoglobin less than or equal to 9 g/dL
    • Absolute neutrophil count greater than or equal to 1.5 x 10^9/L
    • Platelet count greater than or equal to 75 x 10^9/L
    • Serum creatinine less than or equal to 1.5 x ULN (upper limit of normal)
    • AST less than or equal to 2.5 x ULN
    • Serum albumin greater than or equal to LLN (lower limit of normal)
    • Total bilirubin less than or equal to ULN
    • Alkaline phosphatase less than or equal to 2.5 x ULN
  • Signed informed consent

Exclusion Criteria:

  • Pre-existing hepatomegaly with disease measures greater than or equal to 2 cm below the costal margin, secondary to malignancy
  • Administration of cancer specific therapy within the following periods prior to study drug initiation:

    • chemotherapy less than 3 weeks prior
    • hormonal therapy less than one week prior
    • radiation therapy less than 2 weeks prior
  • Be pregnant or lactating; not employing effective birth control
  • Known central nervous system (CNS) metastases unless treated, clinically stable and not requiring steroids
  • Clinical evidence of bowel obstruction, active uncontrolled malabsorption syndromes or a history of total gastrectomy
  • Administration of any investigational agent (therapeutic or diagnostic) within 4 weeks prior to receipt of study medication
  • Uncontrolled hypercalcemia (serum calcium-corrected greater than 12 mg/dL)
  • Serious cardiac condition
  • Any medical conditions that, in the investigator's opinion would impose excessive risk to the patient
  • Patients with previous malignancies unless free of recurrence for at least 5 years except basal cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix
  • Treatment with antiretroviral therapy metabolized through CYP3A4
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Carolyn Sidor, Chief Medical Officer, Miikana Therapeutics, an EntreMed Company
CASI Pharmaceuticals, Inc.
Not Provided
Not Provided
CASI Pharmaceuticals, Inc.
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP